Drug Trial Radar · NCT01761968
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 2013
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis following core protocols in chronic myeloproliferative neoplasms and/or patient-named compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments). Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments), they will be treated at the last tolerable dose of the combination. Assessment of safety and efficacy will be performed at each quarterly visit and each visit will also include laboratory tests and ECG examination. During the visits the clinical benefit will be assessed by Investigator according to the revised European LeukemiaNet response criteria (for PV and ET) and EUMNET response criteria (for MF). The dose of Givinostat will be modified for protocol specified toxicities. The treatment may continue up to Marketing Authorization of givinostat, currently planned in the next 5 years (note: only for Germany, this long-term study is initially limited up to 2 years of treatment). Patients may discontinue study treatment at any time and remain on study therapy as long as they derive clinical benefit. Safety will be monitored at each visit throughout the entire duration of the study. In case the approved label will not cover the whole study population, givinostat will be provided by the Sponsor to those patients not fulfilling the criteria for the approved label of the drug that are still deriving benefit from givinostat at the time of its commercial availability.
Conditions
- Chronic Myeloproliferative Neoplasms
Interventions
givinostatDrug
Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each. If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety and efficacyTime frame: 3 months
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Charite Research Organization GmbH
Berlin, Germany
Universitaetsklinikum Freiburg, Innere Medizin I - Haematologie und Onkologie
Freiburg im Breisgau, Germany
Azienda Ospedaliera Universitaria Università degli Studi "Federico II", Naple
Naples, Italy
Università "Campus Bio-Medico", Rome
Rome, Italy
Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari
Bari, BA, Italy
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico di Bari
Bari, BA, Italy
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, BG, Italy
Azienda Ospedaliero-Universitaria Careggi, Florence
Florence, FI, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico UOS Oncoematologia anziano
Milan, MI, Italy
Azienda Unità Sanitaria Locale - Presidio Ospedaliero "Spirito Santo", Pescara
Pescara, PE, Italy
Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia
Pavia, PV, Italy
Azienda Ospedaliera "Bianchi-Melacrino-Morelli"
Reggio Calabria, RC, Italy
Ospedale San Bortolo, Vicenza
Vicenza, VI, Italy
Belfast City Hospital
Belfast, United Kingdom
Royal Cornwall Hospital
Truro, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.